A new priority policy for patients with hepatocellular carcinoma awaiting liver transplantation within the model for end-stage liver disease system
MetadataShow full item record
The best prioritization of patients with hepatocellular carcinoma (HCC) waiting for liver transplantation under the model for end-stage liver disease (MELD) allocation system is still being debated. We analyzed the impact of a MELD adjustment for HCC, which consisted of the addition of an extra score (based on the HCC stage and waiting time) to the native MELD score. The outcome was analyzed for 301 patients with chronic liver disease listed for liver transplantation between March 1, 2001 and February 28, 2003 [United Network for Organ Sharing (UNOS)-Child-Turcotte-Pugh (CTP) era, 163 patients, 28.8% with HCC] and between March 1, 2003 and February 28, 2004 (HCC-MELD era, 138 patients, 29.7% with HCC). In the HCC-MELD era, the cumulative dropout risk at 6 months was 17.6% for patients with HCC versus 22.3% for those patients without HCC (P = NS), similar to that in the UNOS-CTP era. The cumulative probability of transplantation at 6 months was 70.3% versus 39.0% (P = 0.005), being higher than that in the UNOS-CTP era for patients with HCC (P = 0.02). At the end of the HCC-MELD era, 12 patients with HCC (29.3%) versus 57 without HCC (58.8%) were still on the list (P = 0.001). Both native and adjusted MELD scores were higher (P < 0.05) and progressed more in patients with HCC who dropped out than in those who underwent transplantation or remained on the list (the initial-final native MELD scores were 17.3-23.1, 15.5-15.6, and 12.8-14.1, respectively). The patients without HCC remaining on the list showed stable MELD scores (initial-final: 15.1-15.4). In conclusion, the present data support the strategy of including the native MELD scores in the allocation system for HCC. This model allows the timely transplantation of patients with HCC without severely affecting the outcome of patients without HCC.
Showing items related by title, author, creator and subject.
Comparison between in toto peach (Prunus persica L. Batsch) supplementation and its polyphenolic extract on rat liver xenobiotic metabolizing enzymes Canistro D; Vivarelli F; Cirillo S; Costa G; Andreotti C; Paolini M (2016)Over the past years, there has been a growing interest in the natural constituents of foods as a potential means of cancer control. To date, epidemiology studies seem to indicate an inverse association between regular ...
Volani C; Doerrrier C; Demetz E; Haschka D; Paglia G; Lavdas AA; Gnaiger E; Weiss G. (2017)Iron is an essential co-factor for several metabolic processes, including mitochondrial respiration, and mitochondria are the major sites of iron-utilization. Cellular iron homeostasis must be tightly regulated, as ...
Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma Chambers JC; Zhang W; Sehmi J; Li X; Wass MN; Van der Harst P; Holm H; Sanna S; Kavousi M; Baumeister SE; Coin LJ; Deng G; Gieger C; Heard-Costa NL; Hottenga JJ; Kühnel B; Kumar V; Lagou V; Liang L; Luan J; Vidal PM; Mateo Leach I; O'Reilly PF; Peden JF; Rahmioglu N; Soininen P; Speliotes EK; Yuan X; Thorleifsson G; Alizadeh BZ; Atwood LD; Borecki IB; Brown MJ; Charoen P; Cucca F; Das D; de Geus EJ; Dixon AL; Döring A; Ehret G; Eyjolfsson GI; Farrall M; Forouhi NG; Friedrich N; Goessling W; Gudbjartsson DF; Harris TB; Hartikainen AL; Heath S; Hirschfield GM; Hofman A; Homuth G; Hyppönen E; Janssen HL; Johnson T; Kangas AJ; Kema IP; Kühn JP; Lai S; Lathrop M; Lerch MM; Li Y; Liang TJ; Lin JP; Loos RJ; Martin NG; Moffatt MF; Montgomery GW; Munroe PB; Musunuru K; Nakamura Y; O'Donnell CJ; Olafsson I; Penninx BW; Pouta A; Prins BP; Prokopenko I; Puls R; Ruokonen A; Savolainen MJ; Schlessinger D; Schouten JN; Seedorf U; Sen-Chowdhry S; Siminovitch KA; Smit JH; Spector TD; Tan W; Teslovich TM; Tukiainen T; Uitterlinden AG; Van der Klauw MM; Vasan RS; Wallace C; Wallaschofski H; Wichmann HE; Willemsen G; Würtz P; Xu C; Yerges-Armstrong LM; Alcohol Genome-wide Association (AlcGen) Consortium; Diabetes Genetics Replication and Meta-analyses (DIAGRAM+) Study; Genetic Investigation of Anthropometric Traits (GIANT) Consortium; Global Lipids Genetics Consortium; Genetics of Liver Disease (GOLD) Consortium; International Consortium for Blood Pressure (ICBP-GWAS); Meta-analyses of Glucose and Insulin-Related Traits Consortium (MAGIC); Abecasis GR; Ahmadi KR; Boomsma DI; Caulfield M; Cookson WO; van Duijn CM; Froguel P; Matsuda K; McCarthy MI; Meisinger C; Mooser V; Pietiläinen KH; Schumann G; Snieder H; Sternberg MJ; Stolk RP; Thomas HC; Thorsteinsdottir U; Uda M; Waeber G; Wareham NJ; Waterworth DM; Watkins H; Whitfield JB; Witteman JC; Wolffenbuttel BH; Fox CS; Ala-Korpela M; Stefansson K; Vollenweider P; Völzke H; Schadt EE; Scott J; Järvelin MR; Elliott P; Kooner JS (2011)Concentrations of liver enzymes in plasma are widely used as indicators of liver disease. We carried out a genome-wide association study in 61,089 individuals, identifying 42 loci associated with concentrations of liver ...